26.31
price down icon0.53%   -0.14
after-market After Hours: 26.31
loading
Xoma Royalty Corp stock is traded at $26.31, with a volume of 171.04K. It is down -0.53% in the last 24 hours and up +5.58% over the past month. XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
See More
Previous Close:
$26.45
Open:
$26.05
24h Volume:
171.04K
Relative Volume:
0.46
Market Cap:
$325.80M
Revenue:
$9.71M
Net Income/Loss:
$-29.96M
P/E Ratio:
-7.5603
EPS:
-3.48
Net Cash Flow:
$-14.79M
1W Performance:
-1.68%
1M Performance:
+5.58%
6M Performance:
-25.34%
1Y Performance:
+21.81%
1-Day Range:
Value
$26.05
$27.42
1-Week Range:
Value
$24.48
$27.42
52-Week Range:
Value
$18.35
$39.92

Xoma Royalty Corp Stock (XOMA) Company Profile

Name
Name
Xoma Royalty Corp
Name
Phone
510-204-7239
Name
Address
2200 POWELL STREET, EMERYVILLE, CA
Name
Employee
13
Name
Twitter
@xomacorp
Name
Next Earnings Date
2025-08-08
Name
Latest SEC Filings
Name
XOMA's Discussions on Twitter

Compare XOMA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XOMA
Xoma Royalty Corp
26.31 327.53M 9.71M -29.96M -14.79M -3.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.82 121.40B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
764.93 83.25B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
728.11 46.39B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.51 43.41B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
292.94 33.09B 5.36B 287.73M 924.18M 2.5229

Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-17-25 Initiated The Benchmark Company Buy
Apr-29-24 Initiated Leerink Partners Outperform
Sep-07-21 Downgrade Wedbush Outperform → Neutral
Jun-29-21 Initiated Aegis Capital Buy
Jan-19-21 Reiterated H.C. Wainwright Buy
Jan-18-18 Reiterated H.C. Wainwright Buy
Oct-17-17 Resumed H.C. Wainwright Buy
Sep-05-17 Upgrade Wedbush Neutral → Outperform
Jun-12-17 Initiated H.C. Wainwright Buy
Nov-14-16 Downgrade Wedbush Outperform → Neutral
Mar-11-16 Reiterated Wedbush Outperform
Jul-23-15 Downgrade Jefferies Buy → Hold
Jul-22-15 Downgrade Ladenburg Thalmann Buy → Neutral
Jul-22-15 Downgrade Piper Jaffray Overweight → Neutral
Oct-10-14 Resumed ROTH Capital Buy
Apr-29-14 Upgrade MLV & Co Hold → Buy
Mar-11-14 Downgrade MLV & Co Buy → Hold
Mar-05-14 Reiterated Ladenburg Thalmann Buy
Oct-31-13 Reiterated MLV & Co Buy
May-09-13 Reiterated Ladenburg Thalmann Buy
May-14-12 Initiated Cowen & Co Outperform
Mar-31-11 Reiterated MLV Capital Buy
Mar-23-11 Reiterated RBC Capital Mkts Outperform
Jan-06-11 Reiterated Ladenburg Thalmann Buy
Jan-04-11 Reiterated Wedbush Outperform
View All

Xoma Royalty Corp Stock (XOMA) Latest News

pulisher
Mar 03, 2026

Layoff Watch: Why is XOMA Royalty Corporation stock going downJuly 2025 WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn

Mar 03, 2026
pulisher
Mar 03, 2026

XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Update - MarketBeat

Mar 03, 2026
pulisher
Mar 02, 2026

XOMA (NASDAQ: XOMA) details 2025 royalty cash, buybacks and litigation costs - Stock Titan

Mar 02, 2026
pulisher
Feb 28, 2026

LVTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

XOMA Royalty Corporation (NASDAQ:XOMA) Receives $60.60 Average Price Target from Brokerages - Defense World

Feb 27, 2026
pulisher
Feb 25, 2026

What Analysts Are Saying About XOMA Royalty Stock - Sahm

Feb 25, 2026
pulisher
Feb 24, 2026

Leerink raises Xoma stock price target on royalty outlook - Investing.com

Feb 24, 2026
pulisher
Feb 24, 2026

XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Feb 24, 2026
pulisher
Feb 22, 2026

MURAMural Oncology PLC Latest Stock News & Market Updates - Stock Titan

Feb 22, 2026
pulisher
Feb 20, 2026

XOMA Royalty to Present at Investor Conferences in March - 富途牛牛

Feb 20, 2026
pulisher
Feb 19, 2026

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right - Intellectia AI

Feb 19, 2026
pulisher
Feb 18, 2026

Biotech royalty player XOMA lines up March investor talks - Stock Titan

Feb 18, 2026
pulisher
Feb 16, 2026

Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 27.4% - MarketBeat

Feb 16, 2026
pulisher
Feb 15, 2026

What drives XOMA Royalty Corporation’s stock priceJuly 2025 Gainers & Smart Swing Trading Alerts - mfd.ru

Feb 15, 2026
pulisher
Feb 14, 2026

XOMA Royalty (NASDAQ:XOMA) Upgraded by TD Cowen to "Hold" Rating - MarketBeat

Feb 14, 2026
pulisher
Feb 13, 2026

Why XOMA Royalty Corporation stock is rated strong buyJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru

Feb 13, 2026
pulisher
Feb 13, 2026

XOMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Feb 13, 2026
pulisher
Feb 12, 2026

Xoma stock rating reinstated as Hold by TD Cowen after Generation Bio acquisition - Investing.com South Africa

Feb 12, 2026
pulisher
Feb 12, 2026

Buyback Watch: What drives XOMA Royalty Corporations stock priceJuly 2025 Market Mood & Risk Controlled Stock Alerts - baoquankhu1.vn

Feb 12, 2026
pulisher
Feb 12, 2026

XOMA Royalty (NASDAQ:XOMA) Upgraded at Zacks Research - Defense World

Feb 12, 2026
pulisher
Feb 11, 2026

XOMA Royalty (NASDAQ:XOMA) Upgraded by Zacks Research to "Hold" Rating - MarketBeat

Feb 11, 2026
pulisher
Feb 10, 2026

XOMA Royalty’s Preferreds Still Offer Compelling Income Despite Call Risk (NASDAQ:XOMA) - Seeking Alpha

Feb 10, 2026
pulisher
Feb 10, 2026

Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout - The Business Journals

Feb 10, 2026
pulisher
Feb 10, 2026

XOMA Completes Acquisition and Delisting of Generation Bio - The Globe and Mail

Feb 10, 2026
pulisher
Feb 10, 2026

XOMA Royalty completes acquisition of Generation Bio for $4.29 per share By Investing.com - Investing.com South Africa

Feb 10, 2026
pulisher
Feb 09, 2026

XOMA Royalty completes acquisition of Generation Bio for $4.29 per share - Investing.com Nigeria

Feb 09, 2026
pulisher
Feb 09, 2026

XOMA Royalty completes acquisition of Generation Bio; GBIO delisted from Nasdaq - Investing.com

Feb 09, 2026
pulisher
Feb 09, 2026

XOMA Royalty Completes Generation Bio Acquisition and Merger - TipRanks

Feb 09, 2026
pulisher
Feb 09, 2026

XOMA Royalty Corporation Completes Acquisition of Generation Bio Co. Through Tender Offer - Quiver Quantitative

Feb 09, 2026
pulisher
Feb 09, 2026

XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. - GlobeNewswire

Feb 09, 2026
pulisher
Feb 09, 2026

Generation Bio (GBIO) director equity cashed out in XOMA acquisition - Stock Titan

Feb 09, 2026
pulisher
Feb 08, 2026

Published on: 2026-02-09 02:34:15 - baoquankhu1.vn

Feb 08, 2026
pulisher
Feb 04, 2026

Gainers Report: What is the next catalyst for XOMA Royalty CorporationShare Buyback & Accurate Intraday Trading Signals - baoquankhu1.vn

Feb 04, 2026
pulisher
Feb 02, 2026

Analysts Set XOMA Royalty Corporation (NASDAQ:XOMA) Target Price at $60.60 - Defense World

Feb 02, 2026
pulisher
Jan 31, 2026

Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 56.7% - MarketBeat

Jan 31, 2026
pulisher
Jan 30, 2026

XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Jan 30, 2026
pulisher
Jan 24, 2026

Analyzing XOMA Royalty (NASDAQ:XOMA) and Ascendis Pharma A/S (NASDAQ:ASND) - Defense World

Jan 24, 2026
pulisher
Jan 21, 2026

Risk Off: What is the next catalyst for XOMA Royalty Corporation2025 Volume Leaders & Short-Term High Return Strategies - baoquankhu1.vn

Jan 21, 2026
pulisher
Jan 20, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - GlobeNewswire Inc.

Jan 20, 2026
pulisher
Jan 18, 2026

Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses - Yahoo Finance

Jan 18, 2026
pulisher
Jan 16, 2026

XOMA Royalty Appoints New Chief Financial Officer - The Globe and Mail

Jan 16, 2026
pulisher
Jan 15, 2026

Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty CorporationXOMA - marketscreener.com

Jan 15, 2026
pulisher
Jan 15, 2026

XOMA Royalty Corp (NASDAQ: XOMA) appoints new CFO, sets pay terms - stocktitan.net

Jan 15, 2026
pulisher
Jan 12, 2026

XOMA Royalty CFO Thomas Burns steps down, Jeffrey Trigilio appointed - Investing.com

Jan 12, 2026
pulisher
Jan 12, 2026

XOMA royalty announces CFO transition - MSN

Jan 12, 2026
pulisher
Jan 12, 2026

XOMA Royalty Corporation Announces CFO Transition as Thomas Burns Steps Down and Jeffrey Trigilio Takes Over - Quiver Quantitative

Jan 12, 2026
pulisher
Jan 12, 2026

Biotech royalty firm XOMA shifts finance leadership after nearly 20 years - Stock Titan

Jan 12, 2026
pulisher
Jan 08, 2026

Is XOMA Royalty Corporation stock a defensive play in 20252025 Investor Takeaways & Reliable Price Breakout Signals - Улправда

Jan 08, 2026
pulisher
Jan 06, 2026

Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulus2026 world cup usa national team quarterfinals top scorers counter attacking tactical prediction breakdown - ulpravda.ru

Jan 06, 2026
pulisher
Jan 05, 2026

Implied Volatility Surging for XOMA Royalty Stock Options - Yahoo Finance

Jan 05, 2026
pulisher
Jan 05, 2026

XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of “Hold” by Analysts - Defense World

Jan 05, 2026

Xoma Royalty Corp Stock (XOMA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$45.68
price down icon 3.69%
$53.83
price down icon 6.87%
$29.72
price up icon 0.68%
$101.95
price down icon 1.78%
$143.57
price down icon 4.21%
biotechnology ONC
$292.94
price down icon 2.03%
Cap:     |  Volume (24h):